ION expands ETF trading capabilities with Tradeweb integration
Anteris Technologies Global Corp. (NASDAQ:AVR) has notified 4C Medical Technologies, Inc. that it will not renew their Second Amended and Restated Supply and License Agreement. The agreement, which covers the supply of ADAPT tissue used in 4C’s production of medical devices for transcatheter mitral valve and tricuspid valve regurgitation therapy, is set to expire on June 1, 2026.
The contract also grants 4C a limited license to Anteris’ sterilization methods in connection with the use of ADAPT tissue. Under the terms of the agreement, it would automatically renew for successive one-year periods unless either party provided written notice of non-renewal at least 180 days before expiration.
Anteris stated that no early termination penalties will be incurred as a result of the non-renewal. According to the company, the termination of the contract does not materially impact its financial results.
This information is based on a statement made in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.